Lethal complications of antipsychotic drug medication

Lader M . Long-term side effects of antipsychotic medication. Clinical Risk 1998; 4: 173–7

Jusic N , Lader M . Post-mortem antipsychotic drug concentrations and unexplained deaths. Br J Psychiatr 1994; 165: 787–91

Reinert RE , Hermann CG . Unexplained deaths during chlorpromazine therapy. J Nerv Ment Dis 1960; 131: 435–42

Working Group of the Royal College of Psychiatrists’ Psychopharmacology Sub-group. The Association between Antipsychotic Drugs and Sudden Death (Council Report CR 57). London: Royal College of Psychiatrists, 1997

Ferrier N . Torsade de Pointes and sudden death. In: Haddad P , Dursun S , Deakin B (eds.) Adverse Syndromes and Psychiatric Drugs: A Clinical Guide. Oxford: Oxford University Press, 2004

Glassman AH , Bigger JT . Antipsychotic drugs: prolonged QT_c interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774–82

Titier K , Girodet P-O , Verdoux H . Atypical antipsychotics. From potassium channels to torsade de pointes and sudden death. Drug Safety 2005; 28: 35–51

Taylor DM . Antipsychotics and QT prolongation. Acta Psychiatr Scand 2003; 107: 85–95

Reilly JG , Ayis SA , Ferrier IN . Thioridazine and sudden unexplained death in psychiatric inpatients. Br J Psychiatry 2002; 180: 515–22

Hennessy S , Bilker WB , Knauss JS . Cardiac arrest and ventricular arrhythmia in patient taking antipsychotic drugs: cohort study using administrative data. BMJ 2002; 325: 1070–2

Ray WA , Meredith S , Thapa B . Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 1161–7

Haddad PM , Anderson IM . Antipsychotic-related QT_c prolongation, torsade de pointes and sudden death. Drugs 2002; 62: 1649–71

Lindstrom E , Farde L , Eberhard J , Haverkamp W . QT_c interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol 2005; 8: 615–29

Kohen D . Neuroleptic malignant syndrome. In: Haddad P , Dursun S , Seakin B (eds.) Adverse Syndromes and Psychiatric Drugs: A Clinical Guide. Oxford: Oxford University Press, 2004

Rosebush PI , Mazurek MF . Neuroleptic malignant syndrome: differential diagnosis, treatment, and medico-legal implications. Essential Psychopharmacol 2003; 5: 187–215

Aditanjee YAA , Mathews T . Epidemiology of neuroleptic malignant syndrome. Clinical Neuropharmacol 1999; 22: 151–8

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition Text revision (DSM-IV-TR). Washington: American Psychiatric Association, 2000

Shalev A , Munitz H . The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986; 73: 337–47

Gratz SS , Simpson GM . Neuroleptic malignant syndrome. Diagnosis, epidemiology and treatment. CNS Drugs 1994; 2: 429–39

Caroff SN , Mann SC , Keck PE . Specific treatment of the neuroleptic malignant syndrome. Biol Psychiat 1998; 44: 378–81

Bristow MF , Kohen D . Predicting the effects of re-challenge with antipsychotics following NMS. A review of cases from a Neuroleptic Malignant Syndrome database. Brain Pharmacol 2002; 1: 181–7

Allison DB , Mentore JL , Heo M . Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96

Melkersson K , Dahl M-L . Adverse metabolic effects associated with atypical antipsychotics. Literature review and clinical implications. Drugs 2004; 64: 701–23